| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Current Ratio | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 | 4.81 |
| Quick Ratio | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 | 4.81 |
| Debt / Equity | -0.02 | 0.29 | 0.21 | 0.14 | 0.07 | -0.30 |
| ROE | 423.57% | -120.95% | -78.20% | -36.75% | -31.86% | 73.37% |
| ROA | -149.96% | -81.82% | -59.49% | -30.76% | -28.40% | -57.09% |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book Value / Share | -16.64 | 1.41 | 2.24 | 6.34 | 6.47 | -1.71 |
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases through innovative therapies. Its lead program, telitacicept, is a novel dual BAFF/APRIL inhibitor designed to target the root causes of autoimmunity by silencing signals that drive harmful B-cell maturation, proliferation, and survival, thereby reducing autoantibody production and downstream tissue damage. This fusion protein aims to serve as a foundational therapy for serious B-cell-mediated conditions such as systemic lupus erythematosus, rheumatoid arthritis, and myasthenia gravis. Telitacicept is approved in China for these indications and supports ongoing efforts in Phase 3 clinical development for additional autoantibody-driven diseases worldwide. Vor Biopharma Inc. operates within the health technology sector, emphasizing targeted biologics to restore immune system balance and address unmet needs in large patient populations across autoimmune disorders. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company combines expertise in biologics development to advance its pipeline in this critical therapeutic area.